Proteomics of ovarian cancer: functional insights and clinical applications

被引:60
作者
Elzek, Mohamed A. [1 ,2 ]
Rodland, Karin D. [2 ]
机构
[1] Egybiotech Res & Biotechnol, Alexandria, Egypt
[2] Pacific NW Natl Lab, Div Biol Sci, Richland, WA 99352 USA
基金
美国国家卫生研究院;
关键词
Ovarian cancer; Proteomics; Biomarker; Drug resistance; Subtypes; GENE-EXPRESSION PROFILES; CELL-LINE; PACLITAXEL-RESISTANCE; MULTIDRUG-RESISTANCE; TRANSFERRIN RECEPTOR; MALIGNANCY ALGORITHM; THERAPEUTIC TARGETS; SERUM BIOMARKERS; ADVANCED-STAGE; BETA-CATENIN;
D O I
10.1007/s10555-014-9547-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
In the past decade, there has been an increasing interest in applying proteomics to assist in understanding the pathogenesis of ovarian cancer, elucidating the mechanism of drug resistance, and in the development of biomarkers for early detection of ovarian cancer. Although ovarian cancer is a spectrum of different diseases, the strategies for diagnosis and treatment with surgery and adjuvant therapy are similar across ovarian cancer types, increasing the general applicability of discoveries made through proteomics research. While proteomic experiments face many difficulties which slow the pace of clinical applications, recent advances in proteomic technology contribute significantly to the identification of aberrant proteins and networks which can serve as targets for biomarker development and individualized therapies. This review provides a summary of the literature on proteomics' contributions to ovarian cancer research and highlights the current issues, future directions, and challenges. We propose that protein-level characterization of primary lesion in ovarian cancer can decipher the mystery of this disease, improve diagnostic tools, and lead to more effective screening programs.
引用
收藏
页码:83 / 96
页数:14
相关论文
共 143 条
[1]
Identification of candidate biomarkers with cancer-specific glycosylation in the tissue and serum of endometrioid ovarian cancer patients by glycoproteomic analysis [J].
Abbott, Karen L. ;
Lim, Jae-Min ;
Wells, Lance ;
Benigno, Benedict B. ;
McDonald, John F. ;
Pierce, Michael .
PROTEOMICS, 2010, 10 (03) :470-481
[2]
Exosomes with immune modulatory features are present in human breast milk [J].
Admyre, Charlotte ;
Johansson, Sara M. ;
Qazi, Khaleda Rahman ;
Filen, Jan-Jonas ;
Lahesmaa, Riitta ;
Norman, Mikael ;
Neve, Etienne P. A. ;
Scheynius, Annika ;
Gabrielsson, Susanne .
JOURNAL OF IMMUNOLOGY, 2007, 179 (03) :1969-1978
[3]
Mass spectrometry-based proteomics [J].
Aebersold, R ;
Mann, M .
NATURE, 2003, 422 (6928) :198-207
[4]
Ovarian cancer: Strategies for overcoming resistance to chemotherapy [J].
Agarwal, R ;
Kaye, SB .
NATURE REVIEWS CANCER, 2003, 3 (07) :502-516
[5]
Proteomic tracking of serum protein isoforms as screening biomarkers of ovarian cancer [J].
Ahmed, N ;
Oliva, KT ;
Barker, G ;
Hoffmann, P ;
Reeve, S ;
Smith, IA ;
Quinn, MA ;
Rice, GE .
PROTEOMICS, 2005, 5 (17) :4625-4636
[6]
Comparative proteomics of ovarian epithelial tumors [J].
An, HJ ;
Kim, DS ;
Park, YK ;
Kim, SK ;
Choi, YP ;
Kang, S ;
Ding, BX ;
Cho, NH .
JOURNAL OF PROTEOME RESEARCH, 2006, 5 (05) :1082-1090
[7]
[Anonymous], 2011, Obstet Gynecol, V117, P742, DOI 10.1097/AOG.0b013e31821477db
[8]
Exosomes in cancer development, metastasis, and drug resistance: a comprehensive review [J].
Azmi, Asfar S. ;
Bao, Bin ;
Sarkar, Fazlul H. .
CANCER AND METASTASIS REVIEWS, 2013, 32 (3-4) :623-642
[9]
Bantscheff M, 2012, ANAL BIOANAL CHEM, V404, P939, DOI 10.1007/s00216-012-6203-4
[10]
New tumor markers: CA125 and beyond [J].
Bast, RC ;
Badgwell, D ;
Lu, Z ;
Marquez, R ;
Rosen, D ;
Liu, J ;
Baggerly, KA ;
Atkinson, EN ;
Skates, S ;
Lokshin, A ;
Menon, U ;
Jacobs, I ;
Lu, K .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2005, 15 :274-281